中国实用外科杂志

中国实用外科杂志 ›› 2010, Vol. 30 ›› Issue (01): 59-62.

• 论著 • 上一篇    下一篇

Cathepsin?D和nm23在乳腺癌蒽环类新辅助化疗中疗效的预测价值

陈毅作a，陈灿铭a，费 菲a，张家新a，陆劲松a，狄根红a，柳光宇a，杨文涛b，陆洪芬b，沈坤炜a，沈镇宙a，邵志敏a，吴 炅a   

  1. 复旦大学附属肿瘤医院乳腺外科 复旦大学上海医学院肿瘤学系 a.乳腺外科 b.病理科，上海 200032
  • 收稿日期:1900-01-01 修回日期:1900-01-01 出版日期:2010-01-12 发布日期:2010-01-12

  • Received:1900-01-01 Revised:1900-01-01 Online:2010-01-12 Published:2010-01-12

PDF

摘要：

目的 探讨乳腺癌病人肿瘤组织中分子生物学标记物的表达与含蒽环类新辅助化疗有效率的关系。方法 检测复旦大学附属肿瘤医院2000年1月至2006年8月173例乳腺癌新辅助化疗病人化疗术前或术后标本中ER、PR、Her?2/neu等15种分子标记物的表达情况，分析这些分子标记物的表达在新辅助化疗中的疗效预测价值。结果 nm23或Cathepsin?D阴性病人化疗疗效显著优于阳性病人，多因素回归分析提示Cathepsin?D是独立的新辅助化疗疗效预测指标。结论 Cathepsin?D可能作为乳腺癌新辅助化疗 (蒽环类)敏感性的独立预测指标。

关键词: 乳腺癌, 新辅助化疗, 预测因子, 免疫组织化学

Abstract:

Cathepsin-D and nm23 provide the predictive value of response to anthracycline-based neoadjuvant chemotherapy in breast cancer CHEN Yi-zuo*, CHEN Can-ming, FEI Fei, et al. *Department of Breast Surgery， Cancer Hospital，Fudan University.Department of Oncology, Shanghai Medical College, Fudan University,Shanghai 200032，China Corresponding author: WU Jiong, E-mail: wujiong1122@vip.sina.com Abstract Objective To investigate the predictive value of biological markers for responsiveness to anthracyline-based regimen in neoadjuvant systemic therapy. Methods Post-operative paraffin-embedded tumor samples from 173 breast cancer patients were examined for expression of ER、PR、Her-2/neu、and other 15 markers by immunohistochemistry, to analyze the predictive value of these biological markers for response to neoadjuvant chemotherapy. Results For the primary tumor, the clinical objective response was 66.47%， 29.48%SD,and 4.05% PD. Pathological complete response was found in 3 cases(1.73%).Negative nm23, and loss of Cathepsin-D were significantly predictive for an effective response to anthracycline-based neoadjuvant chemotherapy. In multivariate logistic regression analysis, only the Cathepsin-D status was found for independent predictive value. Conclusion Loss of Cathepsin-D independently predicts the response to anthracycline-based regimen.

Key words: Breast cancer, Neoadjuvant chemotherapy, Predictive factors, Immunohistochemistry